Genital warts

References

Key articles

Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010 Sep-Oct;23(5):458-76. Abstract

Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease. Dermatol Clin. 2006 Apr;24(2):157-65. Abstract

Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. Clin Infect Dis. 1999 Jan;28 Suppl 1:S37-56. Abstract

Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.Full text  Abstract

Reference articles

1. Mansur CP. Human papillomaviruses. In: Tyring SK, ed. Mucocutaneous manifestations of viral diseases. New York, NY: Marcel Dekker; 2002:247-94.

2. Wikström A. Clinical and serological manifestations of genital human papillomavirus infection. Acta Derm Venereol Suppl (Stockh). 1995;193:1-85. Abstract

3. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S210-24.Full text  Abstract

4. Czelusta AJ, Evans T, Arany I, et al. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs. 1999 May;11(5):319-32. Abstract

5. Kirnbauer R, Lenz P, Okun MM. Human papillomavirus. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology Vol 1. London: Mosby; 2003:1217-33.

6. Beutner KR, Reitano MV, Richwald GA, et al. External genital warts: report of the American Medical Association consensus conference. Clin Infect Dis. 1998 Oct;27(4):796-806. Abstract

7. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually transmitted diseases. Part II. Am Acad Dermatol. 1999 Nov;41(5 Pt 1):661-77. Abstract

8. McQuillan G, Kruszon-Moran D, Markowitz LE, et al. Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014. NCHS Data Brief. 2017 Apr;(280):1-8.Full text  Abstract

9. Centers for Disease Control and Prevention. Sexually transmitted infections prevalence, incidence, and cost estimates in the United States. January 2021 [internet publication].Full text

10. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8. Abstract

11. Public Health England. Sexually transmitted infections and screening for chlamydia in England, 2020. September 2021 [internet publication].Full text

12. Severson J, Evans TY, Lee P, et al. Human papillomavirus infections: epidemiology, pathogenesis, and therapy. J Cutan Med Surg. 2001 Jan-Feb;5(1):43-60. Abstract

13. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010 Sep-Oct;23(5):458-76. Abstract

14. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010 May 25;401(1):70-9.Full text  Abstract

15. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012 Nov 20;30 Suppl 5:F55-70.Full text  Abstract

16. Beutner KR, Reitano MV, Richwald GA, et al. External genital warts: report of the American Medical Association consensus conference. Clin Infect Dis. 1998 Oct;27(4):796-806. Abstract

17. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004 Jan;57(1):68-72.Full text  Abstract

18. Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease. Dermatol Clin. 2006 Apr;24(2):157-65. Abstract

19. Meyer T, Arndt R, Christophers E, et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions. J Infect Dis. 1998 Jul;178(1):252-5. Abstract

20. Handsfield HH. Clinical presentation and natural course of anogenital warts. Am J Med. 1997 May 5;102(5A):16-20. Abstract

21. Nebesio CL, Mirowski GW, Chuang TY. Human papillomavirus: clinical significance and malignant potential. Int J Dermatol. 2001 Jun;40(6):373-9. Abstract

22. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004 Jan 1;189(1):46-50.Full text  Abstract

23. Vetrano G, Lombardi G, Di Leone G, et al. Cervical intraepithelial neoplasia: risk factors for persistence and recurrence in adolescents. Eur J Gynaecol Oncol. 2007;28(3):189-92. Abstract

24. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003 Oct 6;89(7):1248-54. Abstract

25. Munk C, Svare EI, Poll P, et al. History of genital warts in 10,838 women 20 to 29 years of age from the general population: risk factors and association with Papanicolaou smear history. Sex Transm Dis. 1997 Nov;24(10):567-72. Abstract

26. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually transmitted diseases. Part II. Am Acad Dermatol. 1999 Nov;41(5 Pt 1):661-77. Abstract

27. Burk RD, Ho GY, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996 Oct;174(4):679-89. Abstract

28. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6. Abstract

29. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med. 2007 Aug-Sep;15(4):130-3. Abstract

30. Henderson Z, Irwin KL, Montaño DE, et al. Anogenital warts knowledge and counseling practices of US clinicians: results from a national survey. Sex Transm Dis. 2007 Sep;34(9):644-52. Abstract

31. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702.Full text  Abstract

32. Yancey AM, Pitlick JM, Forinash AB. The prophylactic role for the human papillomavirus quadrivalent vaccine in males. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1314-8. Abstract

33. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011 Feb 3;364(5):401-11. Abstract

34. Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):229-33.Full text  Abstract

35. Immunization Expert Work Group, Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists. Committee opinion no. 704: human papillomavirus vaccination. Obstet Gynecol. 2017 Jun;129(6):e173-8. Abstract

36. Albero G, Castellsagué X, Giuliano AR, et al. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis. 2012 Feb;39(2):104-13. Abstract

37. Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016 Aug 15;63(4):519-27.Full text  Abstract

38. Mariani L, Vici P, Suligoi B, et al. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015 Jan;32(1):10-30.Full text  Abstract

39. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013 Apr 18;346:f2032.Full text  Abstract

40. Brodell LA, Mercurio MG, Brodell RT. The diagnosis and treatment of human papillomavirus-mediated genital lesions. Cutis. 2007 Apr;79(4 Suppl):5-10. Abstract

41. Steinberg JL, Cibley LJ, Rice PA. Genital warts: diagnosis, treatment, and counseling for the patient. Curr Clin Top Infect Dis. 1993;13:99-122. Abstract

42. Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. Clin Infect Dis. 1999 Jan;28 Suppl 1:S37-56. Abstract

43. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003 Oct 6;89(7):1248-54. Abstract

44. Munk C, Svare EI, Poll P, et al. History of genital warts in 10,838 women 20 to 29 years of age from the general population: risk factors and association with Papanicolaou smear history. Sex Transm Dis. 1997 Nov;24(10):567-72. Abstract

45. Burk RD, Ho GY, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996 Oct;174(4):679-89. Abstract

46. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.Full text  Abstract

47. Habif TP, Campbell JL, Dinulos J, et al. Skin disease diagnosis and treatment. Philadelphia, PA: Elsevier Mosby; 2005:165-9.

48. Wolff K, Johnson RA, Suurmond D. Fitzpatrick's color atlas and synopsis of clinical dermatology. New York, NY: McGraw-Hill; 2005:204-5, 224, 762-4, 893-7, 1034.

49. McCalmont TH. Adnexal neoplasms. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology Vol 2. London, UK: Mosby; 2003:1747-8.

50. Clinical info HIV.gov. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Aug 2021 [internet publication].Full text

51. Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). United Kingdom national guidelines on the management of anogenital warts 2015. Apr 2015 [internet publication].Full text

52. Tyring SK, Edwards L, Friedman DJ, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol. 1998 Jan;134(1):33-8.Full text  Abstract

53. Gotovtseva EP, Kapadia AS, Smolensky MH, et al. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis. 2008 Apr;35(4):346-51. Abstract

54. Tatti S, Stockfleth E, Beutner KR, et al. Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol. 2010 Jan;162(1):176-84. Abstract

55. Gross G, Meyer KG, Pres H, et al. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1404-12. Abstract

56. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol. 2008 Jun;158(6):1329-38. Abstract

57. Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts; a randomized controlled trial. Obstet Gynecol. 2008 Jun;111(6):1371-9. Abstract

58. Bertolotti A, Dupin N, Bouscarat F, et al. Cryotherapy to treat anogenital warts in nonimmunocompromised adults: systematic review and meta-analysis. J Am Acad Dermatol. 2017 Sep;77(3):518-26. Abstract

59. Godley MJ, Bradbeer CS, Gellen M, et al. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med. 1987 Dec;63(6):390-2. Abstract

60. Ying Z, Li X, Dang H. 5-aminolevulinic acid-based photodynamic therapy for the treatment of condylomata acuminata in Chinese patients: a meta-analysis. Photodermatol Photoimmunol Photomed. 2013 Jun;29(3):149-59. Abstract

61. Czelusta A, Yen-Moore A, Van der Straten M, et al. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 2000 Sep;43(3):409-32. Abstract

62. Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS. 2002 Feb 15;16(3):447-50. Abstract

63. Orlando G, Fasolo MM, Signori R, et al. Impact of highly active antiretroviral therapy on clinical evolution of genital warts in HIV-1 infected patients. AIDS. 1999 Feb 4;13(2):291-3. Abstract

64. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS. 1999 Dec 3;13(17):2397-404. Abstract

65. Petersen CS, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med. 1995 Apr;71(2):92-3. Abstract

66. Chuang TY, Ilstrup DM, Perry HO, et al. Condyloma acuminatum in Rochester, Minnesota, 1950-1978. II. Anaplasias and unfavorable outcomes. Arch Dermatol. 1984 Apr;120(4):476-83. Abstract

67. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med. 1995 Oct 5;333(14):943-4. Abstract

68. Orlando G, Fasolo MM, Beretta R, et al. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-infected patients. AIDS. 1999 Oct 1;13(14):1978-80. Abstract

69. Schurmann D, Bergmann F, Temmesfeld-Wollbrück B, et al. Topical cidofovir is effective in treating extensive penile condyloma acuminata. AIDS. 2000 May 26;14(8):1075-6. Abstract

70. Zabawski EJ, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):741-5. Abstract

71. Woodward C, Fisher MA. Drug treatment of common STDs: Part II. Vaginal infections, pelvic inflammatory disease and genital warts. Am Fam Physician. 1999 Oct 15;60(6):1716-22. Abstract

72. Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg. 1989 Oct;76(10):1067-8. Abstract

73. Hawkes AP, Kronenberger CB, MacKenzie TD, et al. Cervical cancer screening: American College of Preventive Medicine practice policy statement. Am J Prev Med. 1996 Sep-Oct;12(5):342-4. Abstract

74. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The hidden epidemic: confronting sexually transmitted diseases. Washington DC: National Academy Press; 1997.

75. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019. July 2021 [internet publication].Full text

Use of this content is subject to our disclaimer